Katarzyna Bartnicka-Maslowska Selected Research

CT-P17

11/2022	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.
1/2021	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katarzyna Bartnicka-Maslowska Research Topics

Disease

2	Rheumatoid Arthritis 11/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

2	CT-P17IBA 11/2022 - 01/2021
2	Adalimumab (Humira)FDA Link 11/2022 - 01/2021
1	Citric Acid (Citrate)FDA LinkGeneric 01/2021
1	Biosimilar PharmaceuticalsIBA 01/2021